Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis
Adam S. Kittai(The Ohio State University Wexner Medical Center), Alexey V. Danilov(Dartmouth–Hitchcock Medical Center), Deborah M. Stephens(University of North Carolina at Chapel Hill), Max J. Gordon(Oregon Health & Science University), Jennifer Bishop(Oregon Health & Science University), Lindsey Fitzgerald(Huntsman Cancer Institute), Nathan Denlinger(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Samantha Jaglowski(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Agrima Mian(Cleveland Clinic), Brian T. Hill(Cleveland Clinic), Ying Huang(Marshall University), Sarah Nagle(Centro de Investigación del Cáncer)
Cited by 60
Related Papers
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Short-term outcomes of complete mesocolic excision versus D2 dissection in patients undergoing laparoscopic colectomy for right colon cancer (RELARC): a randomised, controlled, phase 3, superiority trial
|The Lancet Oncology|2021|184
Immune Checkpoint Inhibitors in Organ Transplant Patients
|Journal of Immunotherapy|2017|150